INHIBITORS OF MET, VEGFR AND RET FOR USE IN THE TREATMENT OF LUNG ADENOCARCINOMA

摘要

This invention is directed to the treatment of cancer in a patient, particularly a patient with lung adenocarcinoma, and more particularly a patient with KIF5B-RET fusion-positive non-small cell lung cancer, with an inhibitor of MET, VEGF, and RET which is a compound of Formula I: or a pharmaceutically acceptable salt thereof.